+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Delcath Systems Inc - logo

Delcath is a pharmaceutical company with a focus on producing medication for oncology. Their drug Melphalan Hydrochloride with the Delcath Hepatic Delivery System (Melphalan/HDS) is used to deliver high doses of chemotherapy to the liver. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system.

Eye Melanoma Market Report 2025 - Product Thumbnail Image

Eye Melanoma Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Biliary Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
From
Unresectable Hepatocellular Carcinoma Market Report 2025 - Product Thumbnail Image

Unresectable Hepatocellular Carcinoma Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2025 - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Bile Duct Neoplasms - Pipeline Insight, 2025 - Product Thumbnail Image

Bile Duct Neoplasms - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Hepatic - Colorectal Metastasis - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic - Colorectal Metastasis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator